Steady-state pharmacokinetics and metabolism of voriconazole in patients

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 11, 2013, Pages 2592-2599

  Geist, Marcus J P ^a   Egerer, Gerlinde ^a   Burhenne, Jürgen ^a   Riedel, Klaus Dieter ^a   Weiss, Johanna ^a   Mikus, Gerd ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Dihydroxy voriconazole; Exposure variability; Hydroxy voriconazole; Therapeutic drug monitoring; Voriconazole N oxide

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DIHYDROXY VORICONAZOLE; DILTIAZEM; DRUG METABOLITE; ERYTHROMYCIN; HYDROXY VORICONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE; VORICONAZOLE N OXIDE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG URINE LEVEL; GENOTYPE; HOSPITALIZATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PROSPECTIVE STUDY; URINALYSIS;

DIHYDROXY-VORICONAZOLE; EXPOSURE VARIABILITY; HYDROXY-VORICONAZOLE; THERAPEUTIC DRUG MONITORING; VORICONAZOLE-N-OXIDE;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; BIOTRANSFORMATION; HUMANS; PLASMA; PROSPECTIVE STUDIES; PYRIMIDINES; TRIAZOLES;

EID: 84886294113     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt229     Document Type: Article

References (35)

1. Johnson LB, Kauffman CA. Voriconazole: a newtriazole antifungal agent. Clin Infect Dis 2003; 36: 630-7.
2. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
3. Purkins L, Wood N, Ghahramani P et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-53.
4. ©. 2012.
5. Mikus G, Schowel V, Drzewinska M et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006; 80: 126-35.
6. Hope WW. Population pharmacokinetics of voriconazole in adults. Antimicrob Agents Chemother 2012; 56: 526-31.
7. Scholz I, Oberwittler H, Riedel KD et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009; 68: 906-15.
8. Donnelly JP, De Pauw BE. Voriconazole: a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect 2004; 10 Suppl 1: 107-17.
9. Roffey SJ, Cole S, Comby P et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003; 31: 731-41.
10. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003; 31: 540-7.
11. Geist MJ, Egerer G, Burhenne J et al. Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype. Antimicrob Agents Chemother 2006; 50: 3227-8.
12. Goldstein JA. Clinical relevance of genetic polymorphisms in thehuman CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-55.
13. Shimizu T, Ochiai H, Asell F et al. Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 2003; 18: 48-70.
14. Ikeda Y, Umemura K, Kondo K et al. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004; 75: 587-8.
15. Rengelshausen J, Banfield M, Riedel KD et al. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005; 78: 25-33.
16. Purkins L,Wood N, Ghahramani P et al. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. Br J Clin Pharmacol 2003; 56 Suppl 1: 30-6.
17. Hassan A, Burhenne J, Riedel KD et al. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit 2011; 33: 86-93.
18. Shah VP, Midha KK, Findlay JWet al. Bioanalytical method validation: a revisit with a decade of progress. Pharm Res 2000; 17: 1551-7.
19. Geist MJ, Egerer G, Burhenne J et al. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Chemother 2007; 51: 3455-6.
20. Lazarus HM, Blumer JL, Yanovich S et al. Safetyand pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002; 42: 395-402.
21. Brüggemann RJ, Blijlevens NM, Burger DM et al. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother 2010; 65: 107-13.
22. Leveque D, Nivoix Y, Jehl F et al. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006; 27: 274-84.
23. Purkins L, Wood N, Greenhalgh K et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56 Suppl 1: 10-6.
24. Keirns J, Sawamoto T, HolumMet al. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob Agents Chemother 2007; 51: 787-90.
25. Weiss J, Ten Hoevel MM, Burhenne J et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009; 49: 196-204.
26. Clifton IJ, Whitaker P, Metcalfe R et al. Pharmacokinetics of oral voriconazole in patients with cystic fibrosis. J Antimicrob Chemother 2011; 66: 2438-40.
27. Dolton MJ, Ray JE, Chen SC et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56: 4793-9.
28. Pascual A, Csajka C, Buclin T et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 2012; 55: 381-90.
29. Mitsani D, Nguyen MH, Shields RK et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 2012; 56: 2371-7.
30. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011; 55: 4782-8.
31. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570-2.
32. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53: 24-34.
33. Dowell JA, Schranz J, Baruch A et al. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005; 45: 1373-82.
34. Hafner V, Czock D, Burhenne J et al. Pharmacokinetics of sulfobutylether-b-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother 2010; 54: 2596-602.
35. Gubbins PO, Amsden JR. Drug-drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother 2005; 6: 2231-43.